Survey
Quarterly Survey: mCRPC and Pluvico Lutetium-177 PSMA Therapy October 2024
Ticker(s): NVSSurvey results include 20 Oncologists.
How many patients with Advanced Metastatic Prostate Cancer are in your practice?
How would you best describe your practice?
- Academic
- Community
- Other
How many of your patients do you consider eligible for Pluvicto (Lutetium-177 vipivotide tetraxetan)?
How many of your patients do you prescribe Pluvicto today?
How many of your patients started Pluvicto in the last 30 days?
How many of your patients discontinued Pluvicto in the last 30 days?
How many total patients do you expect to be on Pluvicto in the next 30 days (cumulative)?
How do you expect usage of Pluvicto in your patients to change moving forward?
In response to your answer above: why is that?
Do you have any concerns regarding the safety profile of Pluvicto?
Have you had any recent experience or issues with availability/supply chain of Pluvicto? If so, has your access increased over time?
How would you rate Pluvicto on the following (where 1 is low and 5 is high)?
- Safety
- Efficacy
- Payor Access
How does Pluvicto compare to the standard of care in the second line setting (taxane- naive) in your practice?
What are your overall impressions of the PSMAfore results?
Would you prescribe PNT-2002 to Pluvicto refractory patients, if approved?
Will incorporating the use of PNT-2002 into your practice require any additional setting resources compared to Pluvicto (e.g., safety procedures, shielding, transportation, technology for administration)?
Assuming the maturity in the Overall Survival Endpoint is approved on the basis of PSMAfore, how do you expect the use of Pluvicto to change within your practice?
Assuming the maturity in the Overall Survival Endpoint is approved on the basis of PSMAfore, please estimate size increase (%), if any, of eligible estimated population?
What is your opinion of alpha emitters as opposed to the beta emitters?
How do you view the potential of radioligand therapies compared to antibody drug conjugates?
Lastly, what do you think about the potential of actinium-based compounds for radioligand therapies as opposed to lutetium?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
